

22 May 2025

**Fusion Antibodies plc  
("Fusion" or the "Company")**

**Update on U.S. Patent for OptiMAL®**

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the United States Patent and Trademark Office has issued a notice of allowance in respect of the Company's U.S. patent application no. 17/287,441 (the "**Patent Application**").

The Patent Application entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL® platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation.

Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.

Further announcements will be made at the appropriate time.

**Enquiries:**

**Fusion Antibodies plc**

Adrian Kinkaid, Chief Executive Officer  
Stephen Smyth, Chief Financial Officer

[www.fusionantibodies.com](http://www.fusionantibodies.com)  
Via Walbrook PR

**Allenby Capital Limited**

James Reeve/Vivek Bhardwaj (Corporate Finance)  
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656

**Shard Capital Partners LLP**

Damon Heath (Joint Broker)

Tel: +44 (0) 207 186 9952

**Walbrook PR**

Anna Dunphy

Tel: +44 (0)20 7933 8780 or [fusion@walbrookpr.com](mailto:fusion@walbrookpr.com)  
Mob: +44 (0)7876 741 001

**About Fusion Antibodies plc**

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx™ platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how

RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDUUUORVKUVUAR